Hepatocellular carcinoma (HCC) developed in non-alcoholic fatty liver disease (NAFLD) individuals presents substantial clinical and biological characteristics, which remain to be elucidated. Its occurrence in noncirrhotic patients raises issues regarding surveillance strategies, which cannot be considered as cost-effective given the high prevalence of obesity and metabolic syndrome, and furthermore delineates specific oncogenic process that could be targeted in the setting of primary or secondary prevention. In this context, the identification of a genetic heterogeneity modulating HCC risk as well as specific biological pathways have been made possible through genome-wide association studies, development of animal models and in-depth analyses of human samples at the pathological and genomic levels. These advances must be confirmed and pursued to pave the way for personalized management of NAFLD-related HCC.
Keyphrases
- public health
- metabolic syndrome
- genome wide association
- end stage renal disease
- insulin resistance
- newly diagnosed
- endothelial cells
- chronic kidney disease
- type diabetes
- risk assessment
- peritoneal dialysis
- copy number
- weight loss
- uric acid
- transcription factor
- gene expression
- single cell
- cardiovascular disease
- signaling pathway
- cancer therapy
- dna methylation
- drug delivery
- high fat diet induced
- body mass index
- bioinformatics analysis